Aligos Announces Abstracts & Late-Breaker Presentation at TLM 2024

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical firm, has announced the acceptance of four abstracts for presentation at the 2024 Liver Meeting organized by the American Association for the Study of Liver Diseases (AASLD). This event will be held from November 15 to November 19, 2024, in San Diego, California. The accepted abstracts include one late-breaking oral presentation and three poster presentations. The details of these abstracts have been published on the AASLD website.

One of the key abstracts focuses on ALG-000184, a potential first-in-class small molecule Capsid Assembly Modulator (CAM-E) for chronic hepatitis B (CHB). Notably, this abstract (Abstract #1213) will be presented by Professor Man-Fung Yuen from the University of Hong Kong. The presentation emphasizes that monotherapy with ALG-000184 results in high viral suppression rates in both HBeAg-positive and HBeAg-negative subjects with chronic hepatitis B or hepatitis B virus (HBV) infection. This presentation will be held on November 15, 2024, from 8:00 am to 5:00 pm PT.

Another notable abstract (Abstract #1266) on ALG-000184 will be presented by Cheng Liu, PhD. This study indicates that Capsid Assembly Modulators like ALG-001075 cause significant HBV DNA knockdown and directly target HBeAg in vitro. This presentation is also scheduled for November 15, 2024, between 8:00 am and 5:00 pm PT.

Additionally, ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), will be discussed in an oral presentation. This presentation will highlight the promising results of ALG-055009 in reducing liver fat at week 12 in non-cirrhotic MASH patients during an ongoing randomized, double-blind, placebo-controlled Phase 2 trial. Dr. Rohit Loomba, from the University of California, San Diego, will present these findings on November 19, 2024, from 10:30 am to 10:40 am PT.

The fourth abstract (Abstract #3226) addresses the nonclinical toxicology profile of ALG-055009, emphasizing its safety and efficacy as a potent Thyroid Hormone Receptor β agonist for treating MASH. This presentation by Dr. Dinah Misner will take place on November 17, 2024, from 8:00 am to 5:00 pm PT.

Aligos Therapeutics, listed on NASDAQ under the ticker ALGS, is dedicated to enhancing patient health by developing leading-edge treatments for liver and viral diseases. The company leverages its scientific expertise and robust research and development capabilities to push forward its specialized pipeline of therapeutics, primarily targeting metabolic dysfunction-associated steatohepatitis (MASH) and high-need viral infections like hepatitis B and coronaviruses.

These presentations at The Liver Meeting 2024 will highlight Aligos Therapeutics’ ongoing commitment to advancing therapeutic options for liver diseases and provide the scientific community with significant insights into the potential of ALG-000184 and ALG-055009. The data presented are expected to underscore the effectiveness and safety of these novel small molecule therapies, further establishing Aligos Therapeutics as a leader in the treatment of liver diseases.